share_log

UPLOAD: Others

UPLOAD: Others

UPLOAD:其他
美股SEC公告 ·  04/18 10:16

牛牛AI助理已提取核心訊息

Adial Pharmaceuticals, Inc. has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on April 12, 2024, will not undergo review by the commission. The SEC's communication, dated April 17, 2024, was addressed to Cary Claiborne, the Chief Executive Officer of Adial Pharmaceuticals. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC has provided contact information for Lauren Hamill.
Adial Pharmaceuticals, Inc. has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on April 12, 2024, will not undergo review by the commission. The SEC's communication, dated April 17, 2024, was addressed to Cary Claiborne, the Chief Executive Officer of Adial Pharmaceuticals. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC has provided contact information for Lauren Hamill.
美國證券交易委員會(SEC)已告知Adial Pharmicals, Inc.,其於2024年4月12日提交的S-3表格的註冊聲明將不接受該委員會的審查。美國證券交易委員會於2024年4月17日致阿迪爾製藥公司首席執行官卡里·克萊伯恩的信函。美國證券交易委員會的信中還提到了與加快註冊程序的請求有關的第460和461條。美國證券交易委員會提醒該公司及其管理層,無論美國證券交易委員會的審查水平如何,他們都有責任確保披露的準確性和充分性。爲了進一步調查,美國證券交易委員會提供了勞倫·哈米爾的聯繫信息。
美國證券交易委員會(SEC)已告知Adial Pharmicals, Inc.,其於2024年4月12日提交的S-3表格的註冊聲明將不接受該委員會的審查。美國證券交易委員會於2024年4月17日致阿迪爾製藥公司首席執行官卡里·克萊伯恩的信函。美國證券交易委員會的信中還提到了與加快註冊程序的請求有關的第460和461條。美國證券交易委員會提醒該公司及其管理層,無論美國證券交易委員會的審查水平如何,他們都有責任確保披露的準確性和充分性。爲了進一步調查,美國證券交易委員會提供了勞倫·哈米爾的聯繫信息。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。